A potential game-changing drug for use in the treatment of a common form of vision loss took a step closer to the FDA in October when Ophthotech (ISEE) announced its second phase 3 trial of Fovista for wet age-related macular edema was now fully enrolled.
Investors cheered the news, sending shares up sharply last month, but can Ophthotech's shares continue to climb? In the following slideshow, I discuss Ophthotech's potential, including why a major deal with Novartis (NVS 1.93%) makes this company an intriguing investment for risk-tolerant investors.
This iSecret stock could make this pop look tiny
The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here.
Why Ophthotech Corporation Soared In October from The Motley Fool.
